广东粤运交通拯救有限公司

What 广东粤运交通拯救有限公司 does

SG胜游医疗科学有限公司 (MicroPort Scientific Corporation) is a Hong Kong-listed (00853.HK) multinational high-end medical device conglomerate founded in 1998 in Shanghai Zhangjiang Science City. The company develops, manufactures, and commercializes interventional and implantable medical devices across 12 major business clusters covering cardiovascular and structural heart disease, cerebrovascular and neurological modulation, peripheral vascular and life-support systems, electrophysiology and cardiac rhythm management, medical AI and robotics, orthopedics and sports medicine, urology and digestive diseases, ophthalmology, endocrinology and reproduction, aesthetic and skincare, and regenerative medicine. Flagship products include the Firehawk® coronary drug-eluting stent (lowest drug dose globally, Lancet-published TARGET AC data), VitaFlow® transcatheter aortic valve system, Columbus® 3D cardiac electrophysiology mapping system, Toumai® laparoscopic surgery robot, SkyWalker® orthopedic surgical robot, R-one® vascular interventional robot, NUMEN® and Tubridge® neurovascular devices, plus a broad portfolio of pacemakers, ICDs, cryoablation systems, and peripheral vascular products. The company holds nearly 12,000 patents globally and has received 5 National Science and Technology Progress Awards.

The company operates through a multi-subsidiary structure with 20+ entities across 12 business clusters, of which five are independently publicly listed (688016.SH, 02160.HK, 02172.HK, 688351.SH, 02252.HK). Distribution is executed through a dual domestic-overseas network: 微联微通 (Weilian Weitong) handles Chinese primary healthcare institution coverage across 100+ cities and all provinces, while 全球通 (Global通) extends reach to 100+ countries and 20,000+ hospitals internationally. The company runs an integrated innovation-to-commercialization pipeline including the 知行学院 (Innovation & Initiation Institute) physician training platform, 良知创意中心 (Creative Conscience Center) doctor-industry collaboration program, 奇迹点® (MiraclePoint) startup incubator, and 良知关爱 patient education center. Products are evenly distributed across Asia-Pacific, Europe, and the Americas, with manufacturing and R&D sites in China (Shanghai, Suzhou, Jiaxing), the United States (Irvine, Memphis), France (Clamart), Italy (Saluggia), Germany (Aachen), the UK (Oxford), and the Dominican Republic.

Revenue is generated through B2B sales of high-end medical devices and disposables to hospitals under procurement and reimbursement frameworks, supplemented by clinical training services, spare parts, and consumables. FY2022 revenue was USD 840.8 million (approximately HKD 6.6 billion) with gross profit of USD 501.8 million and R&D spending of USD 419.8 million (~50% of revenue), reflecting a capital-intensive reinvestment model. The customer base is highly diversified across 20,000+ healthcare institutions, with no single customer concentration risk observable in the dataset.

Name

广东粤运交通拯救有限公司

Legal name

MicroPort Scientific Corporation Limited (SG胜游医疗科学有限公司)

Website

https://yyjtzj.com

Company type

Public

Founded year

1998

Operating status

Operating

Short description

SG胜游医疗科学有限公司 (MicroPort Scientific Corporation) is a Hong Kong-listed multinational medical device conglomerate developing high-end interventional and implantable devices across cardiovascular, neurovascular, electrophysiology, surgical robotics, and orthopedics, serving 20,000+ hospitals across 100+ countries through a multi-subsidiary structure and dual domestic-international distribution network.

Ownership category

akta.pro rank

Product category

Interventional Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Interventional medical devices
• Cardiovascular implants
• Neurovascular devices
• Surgical robotics
• Medical device distribution

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices13 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Product Sales: SG胜游 generates revenue primarily through the sale of proprietary high-end medical devices across 12 major business clusters covering cardiovascular, neurovascular, peripheral vascular, electrophysiology, robotics, orthopedics, urology, gynecology, ophthalmology, and aesthetics. Products are sold directly to hospitals and through distributor networks.
2. Aftermarket Services and Training: Revenue from clinical training services through 知行学院 (Innovation & Initiation Institute), spare parts, and consumables for deployed medical devices.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

The company distributes and sells a comprehensive portfolio of high-end interventional and implantable medical devices, including coronary drug-eluting stents, transcatheter aortic valve systems, neurovascular embolization coils and flow diverters, aortic stent grafts, peripheral vascular devices, electrophysiology mapping and ablation systems, implantable pacemakers and defibrillators, ECMO and life-support systems, and surgical/orthopedic robotics. The website lists hundreds of named SKUs spanning 12 medical device business clusters, with named products including Firehawk®, VitaFlow Liberty®, Columbus®, Toumai®, SkyWalker®, Castor®, and Tubridge®. The site also operates an innovation incubator (奇迹点®), a physician training academy (创新知行学院), a doctor-industry collaboration center (良知创意中心), and a patient education center (良知关爱).

Product overview

SG胜游®集团 is a diversified, globally-operating high-tech medical device conglomerate with a portfolio spanning 12 major business clusters: cardiovascular and structural heart disease, cerebrovascular and neurological modulation, peripheral vascular and life-support systems, electrophysiology and cardiac rhythm management, medical AI and robotics, orthopedics and sports medicine, urology and digestive diseases, ophthalmology and respiratory care, cancer treatment and life保障, endocrine diagnostics and reproduction, synthetic biology and regenerative medicine, and aesthetic and functional skincare. The group operates multiple listed subsidiaries (MicroPort CardioFlow, MicroPort NeuroTech, MicroPort MedBot, MicroPort EP MedTech, Shanghai MicroPort Endovastec) and offers hundreds of medical solutions covering cardiac stents, TAVR systems, electrophysiology mapping and ablation, pacemakers, surgical robots, orthopedic implants, cryoablation, insulin pumps, IVF products, and skincare. Its products are deployed in over 20,000 hospitals across 100+ countries, with a new product launched approximately every 5 seconds globally.

Differentiator

Problem solved

Functional benefit

Brands

• 心脉医疗: Endovascular stent grafts and large vessel diseases subsidiary, publicly listed on Shanghai STAR Market (688016.SH)
• 心通医疗
• SG胜游脑科学
• SG胜游电生理
• SG胜游机器人 / MicroPort MedBot
• 微联微通
• 奇迹点孵化器Plus
• 良知关爱
• 创新知行学院
• 良知创意中心
• 创领心律医疗
• CRM (MicroPort Cardiac Rhythm Management)
• MicroPort Orthopedics

Products and services

• Intravascular Imaging and Diagnostic Systems (Decypher™ IVUS, ArgusClarity® OCT, PICCO hemodynamic monitor)
• Urology and Gynecology Devices (EZ-UroGuide®, EZ-Captcher® stone baskets, Lotus™ assisted reproduction)
• Insulin Pump and Endocrine Devices (La Fenice® / 火凤凰® insulin pump, Ticker™ AI box)
• Tumor Cryoablation and Aesthetic Product Lines (TACTIC™ tumor cryoablation, REVEDA® functional skincare)
• Coronary Drug-Eluting Stent Systems (Firehawk®, Firebird2®, FireKingFisher®, Firecondor®, Firesorb®, Firelimus®, Firebird Pro+®)
• Transcatheter Aortic Valve Systems (VitaFlow®, VitaFlow Liberty®, Alwide®Plus, AnchorMan®)
• Neurovascular Devices (NUMEN® embolization coils, Tubridge® flow diverter, NeuroHawk®, Tigertriever®, WILLIS®, Bridge® vertebral stent, APOLLO™)
• Aortic Stent Grafts (Castor®, Hercules® Low Profile, Talos®, Aegis®, Minos®, Fontus®, CRONUS®)
• Peripheral Vascular Devices (Reewarm®, Ryflumen®, Vflower® venous stent, Fishhawk®, L-REBOA®, Vewatch® IVC filter, VEPACK®)
• Electrophysiology Systems (Columbus® 3D mapping, FireMagic® ablation, IceMagic® cryoablation, OptimAblate®, EasyFinder®, EasyLoop®, PathBuilder®, magnetic navigation Niobe®)
• Implantable Pacemakers and ICDs (Rega®, Trefle®, Orchidee®, ESPRIT, Reply, ENO, Beflex, Vega, Bonafire, Platinium™)
• ECMO and Cardiopulmonary Bypass Systems (VitaSprings® membrane oxygenator, Pump N'Run® centrifugal pump, SleekFlow® cannulae, Infinity115™ system)
• Surgical and Orthopedic Robotic Systems (Toumai® laparoscopic robot, SkyWalker® orthopedic navigation, R-one® vascular robot, DFVision® 3D endoscope, iSR'obot® Mona Lisa prostate biopsy robot)
• Structural Heart and Congenital Heart Occluders (Evermend® 怡心® ASD/VSD/PDA occluders, AnchorMan® left atrial appendage occluder, THUNDERBIRD® hernia patch)

Quantifiable outcome

• Firehawk® stent uses only 1/3 of the drug dose of competitors while maintaining equivalent safety and efficacy (TARGET AC 5-year follow-up, zero stent thrombosis rate; Lancet publication)
• +5 more outcomes

Named customers6 records

Segments7 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Hemovent (Germany)minorStrategic or Co-development Partner · 1 January 2024Hemovent's MOBYO™ membrane lung obtained EU approval; SG胜游 holds strategic investment in Hemovent.
• NDR (Singapore percutaneous navigation robot company)minorStrategic or Co-development Partner · 1 January 2021SG胜游 entered strategic investment agreement and joint venture agreement with Singapore-based NDR for percutaneous navigation robot technology in China.
• Robocath (France vascular interventional robot company)minorStrategic or Co-development Partner · 1 January 2021SG胜游 entered strategic investment agreement and joint venture agreement with France-based Robocath for vascular interventional robotics in China.
• Siemens Healthineers (西门子医疗)coreStrategic or Co-development Partner · 1 January 2021SG胜游 entered strategic cooperation with Siemens Healthineers covering medical angiography X-ray systems.
• Purple Medical (India)minorStrategic or Co-development Partner · 1 January 2021SG胜游 made strategic investment in India-based Purple Medical and established a joint venture company.
• 4C Medical (US)minorStrategic or Co-development Partner · 1 January 2021心通医疗 invested in 4C Medical (US) and its AltaValve™ product received FDA breakthrough device designation for two treatment indications.
• LivaNova (UK/Sorin)coreStrategic or Co-development Partner · 1 January 2019SG胜游 acquired LivaNova's cardiac rhythm management business for approximately USD 190 million cash, establishing CRM global headquarters in Paris.

Scale indicators8 records

Recent moves6 records

Expansion highlights10 records

Direct peers

• Medtronic: Global leader in cardiovascular, structural heart, CRM, neurovascular, and surgical devices — direct peer across nearly every MicroPort franchise at scale, and the most established incumbent MicroPort competes against in US/EU and China.
• Boston Scientific: Direct competitor in coronary stents, peripheral vascular, electrophysiology (mapping/ablation), and structural heart — closely comparable product portfolio and global distribution footprint.
• Edwards Lifesciences: Pure-play TAVR leader (Sapien platform) and structural heart incumbent. The closest head-to-head competitor to MicroPort's VitaFlow TAVR franchise, including in EU and emerging markets.
• Abbott Laboratories: Major peer across coronary stents (Xience), structural heart (Portico), CRM (pacemakers/ICDs), and neurovascular — comparable in cardiovascular breadth and global footprint.
• Stryker: Direct peer in orthopedics (knee/hip implants, MAKO robotics) — competes against MicroPort Orthopedics in both reconstructive implants and robotic surgical navigation.
• Intuitive Surgical: Global leader in surgical robotics (da Vinci); competes directly with MicroPort MedBot's Toumai laparoscopic platform in China and selected international markets.
• Penumbra: Specialist in neurovascular thrombectomy and peripheral vascular — competes with MicroPort NeuroTech (Tigertriever, WAVE-track) and Fishhawk peripheral thrombectomy products.
• Zimmer Biomet: Global orthopedic reconstructive implant leader — comparable peer to MicroPort Orthopedics in knee/hip replacement and adjacent robotic navigation.

Emerging players

• Robocath: France-based vascular interventional robotics company in which MicroPort has strategic investment and a China JV — adjacent emerging player in robotic PCI where MicroPort is building presence via R-one.
• Shockwave Medical: Intravascular lithotripsy leader in coronary and peripheral vascular — emerging peer to MicroPort's Firehawk, TomaHawk shock wave, and peripheral vascular franchises in the same call points.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 广东粤运交通拯救有限公司